New federal board gets binding veto over risky life sciences research funding
S. 854 — Risky Research Review Act · Filed by Rand Paul (R-KY) · 1 cosponsor · Introduced Mar 5, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new independent federal agency called the Life Sciences Research Security Board to review and approve all federal funding for high-risk life sciences research before money is awarded. The Board—composed of 9 members including scientists, national security experts, and a biosafety expert—has binding authority to block, approve, or impose safety conditions on research involving dangerous pathogens or gain-of-function experiments. Researchers and funding agencies must attest to whether proposed work is high-risk, and the Board has 120 days to decide whether funding can proceed.
Why we flagged it
The bill's core function is to establish an independent expert board with binding authority over federal funding for high-risk life sciences research, particularly gain-of-function and dual-use research involving dangerous pathogens. This is a regulatory/oversight mechanism, not a subsidy, tax provision, or commemorative act.
What the text implies
- The Board's definition of 'high-risk life sciences research' is self-expanding: the Board can unilaterally add new categories by majority vote and Federal Register publication, with no congressional override mechanism, potentially capturing research far beyond the stated pathogen list.
- The 120-day review clock does not stop for Board requests for additional information, creating pressure on agencies to submit incomplete applications or face indefinite delays—a procedural advantage to the Board's authority.
The full analysis lists 5 implications of this text.
Who it affects
The bill creates a genuine public-safety mechanism: independent expert review of federally funded research that could produce pandemic pathogens or bioweapons, with binding enforcement and transparency requirements. However, the Board's broad discretion to define what counts as high-risk research, combined with vague risk-benefit balancing language and no explicit public participation or appeal process, creates capture risk and potential for research chilling effects without clear offsetting pub